Log in
NASDAQ:ALEC

Alector Stock Forecast, Price & News

$9.81
+0.32 (+3.37 %)
(As of 10/26/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.32
Now: $9.81
$9.86
50-Day Range
$9.40
MA: $11.29
$14.14
52-Week Range
$9.21
Now: $9.81
$35.93
Volume734,524 shs
Average Volume1.01 million shs
Market Capitalization$777.54 million
P/E RatioN/A
Dividend YieldN/A
Beta0.55
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer's disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALEC
CUSIPN/A
CIKN/A
Phone415-231-5660
Employees153

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.22 million
Book Value$2.83 per share

Profitability

Net Income$-105,390,000.00
Net Margins-775.34%

Miscellaneous

Market Cap$777.54 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$9.81
+0.32 (+3.37 %)
(As of 10/26/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alector (NASDAQ:ALEC) Frequently Asked Questions

How has Alector's stock been impacted by COVID-19 (Coronavirus)?

Alector's stock was trading at $24.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALEC shares have decreased by 60.6% and is now trading at $9.81.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Alector?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Alector
.

When is Alector's next earnings date?

Alector is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Alector
.

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) issued its earnings results on Tuesday, August, 11th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.09. The firm had revenue of $3.17 million for the quarter, compared to analyst estimates of $8.84 million. Alector had a negative net margin of 775.34% and a negative return on equity of 50.88%.
View Alector's earnings history
.

What price target have analysts set for ALEC?

8 Wall Street analysts have issued 1-year price targets for Alector's stock. Their forecasts range from $28.00 to $41.00. On average, they expect Alector's stock price to reach $32.80 in the next twelve months. This suggests a possible upside of 234.4% from the stock's current price.
View analysts' price targets for Alector
.

Are investors shorting Alector?

Alector saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 10,670,000 shares, an increase of 26.6% from the September 15th total of 8,430,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is presently 10.5 days. Currently, 19.1% of the company's shares are sold short.
View Alector's Short Interest
.

Who are some of Alector's key competitors?

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

Who are Alector's key executives?

Alector's management team includes the following people:
  • Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 56, Pay $49.44k)
  • Dr. Arnon Rosenthal, Co-Founder, CEO & Director (Age 64, Pay $869.81k)
  • Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 52, Pay $581.55k)
  • Dr. Robert S. King, Chief Devel. Officer (Age 57, Pay $531.57k)
  • Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Pres & COO (Age 48)
  • Mr. Calvin Yu, VP of Fin. (Age 43)
  • Mr. Charles Wolfus, VP of Technology & Digital Health
  • Mr. Brian Sander J.D., Ph.D., Gen. Counsel
  • Ms. Clare Hunt M.B.A., Head of People
  • Dr. Sabah Oney Ph.D., Chief Bus. Officer (Age 37)

When did Alector IPO?

(ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Who are Alector's major shareholders?

Alector's stock is owned by a variety of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.20%), Exane Derivatives (0.01%) and Exane Derivatives (0.01%). Company insiders that own Alector stock include Calvin Yu, David M Wehner, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney and Terrance Mcguire.
View institutional ownership trends for Alector
.

Which institutional investors are buying Alector stock?

ALEC stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Exane Derivatives, and Exane Derivatives. Company insiders that have bought Alector stock in the last two years include David M Wehner, and Orbimed Advisors Llc.
View insider buying and selling activity for Alector
.

How do I buy shares of Alector?

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $9.81.

How big of a company is Alector?

Alector has a market capitalization of $777.54 million and generates $21.22 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 153 workers across the globe.

What is Alector's official website?

The official website for Alector is www.alector.com.

How can I contact Alector?

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]

This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.